

9P-Long term recurrence risk predictions by CanAssist Breast in a sub-cohort of TEAM

<u>Xi Zhang^{2*}, A. Gunda¹, E. Meershoek-Klein Kranenbarg², P.J.K Kuppen², B.A. Savitha¹, C. Prakash¹, P. Srivastava¹, T. Kaur¹, C. Seynaeve³, G.-J.</u> Liefers^{2,4}, M. Siraganahalli Eshwaraiah¹, C.J.H van de Velde^{2,} Manjiri M Bakre^{1@} ¹Research and Development, OncoStem Diagnostics Pvt Ltd, Bangalore, India, ²Surgery, Leiden University Medical Center, Leiden, the Netherlands, ³Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands, ⁴Geriatric Oncology Research Group, Leiden University Medical Center, Leiden, the Netherlands * First and Presenting author, @ Corresponding author <u>manjiri@oncostemdiagnostics.com</u>

Abstract

Background: CanAssist Breast (CAB) is an IHC based prognostic test that predicts the risk of distant recurrence in hormone receptor (HR) positive, HER2 negative early breast cancer within 5 years from diagnosis. CAB has been validated extensively on retrospective cohorts from India, USA and Europe showing its comparable performance across these divergent cohorts. The current study for the first time demonstrates the recurrence risk predictions up to 10 years in a sub-cohort of a prospective clinical trial, TEAM (Tamoxifen, Exemestane Adjuvant Multinational).

Methods: CAB has been assessed on 480 Dutch patient tumor samples (FFPE embedded) enrolled in the TEAM trial from 22 centres. TEAM is a large, international clinical trial that recruited 9766 post-menopausal women, randomized for the use of hormonal therapy, sequential (2-3 years Tamoxifen + 3-2 years exemestane) or exemestane alone (5 years) and patients were followed up for at least 10 years (median=10.4, 95% CI:10.3-10.6, range: 0.93-15.45). The investigators performing CAB were blinded to clinical outcomes. The recurrence risk predictions by CAB were compared with patient outcomes by the LUMC team. Of 480 patients, the current analysis is restricted to 434 HER2 negative patients. The performance of CAB was estimated with Kaplan-Meier survival analysis and hazard ratios (HR) by log rank test.

Results: Our study cohort had 68.4% patients with node-positive disease, 55.6% had tumors greater than 2cm (T2) and 25.8% had poorly differentiated tumors (G3). 79.3% of the cohort was treated with hormonal therapy alone, either exemestane alone or sequential therapy for a period of 5 years. CAB stratified 68% of the total cohort as low risk and 32% as high risk. All-cause mortality was 39% in CAB low risk and it was 44% in CAB high risk (HR:1.45 (0.99-2.1),p=0.04). Distant event rates and death due to breast cancer were 11% in CAB low-risk and 30% in CAB high-risk (HR: 2.91 (1.76-4.82), p=0.0001). CAB risk stratification across both the arms of hormonal therapy was significant with an HR of 4.76 (2.26-10), P<0.0001 in the exemestane arm and an HR of 2 (1-3.99), P=0.026 in the sequential arm. CAB risk stratification was not influenced by chemotherapy, and it was significant in the total cohort and across both the arms of hormonal therapy. In node-positive sub-cohort HR for CAB was significant and greater than 2 in the total cohort and in both the arms, with event (distant metastasis and death due to breast cancer) rates of 9% in the exemestane arm. CAB predicted the benefit of exemestane for low-risk (HR: 1.78 (1.07-2.94), P=0.02) and chemotherapy for high-risk patients (HR: 2.76) (1.44-5.23), P=0.016). CAB risk score had a higher and significant HR of 2.48 (1.52-4.08), P=0.0003 over clinical parameters, tumor size, node status and histological grade.

Conclusions: Data from a randomised trial show the usefulness of CAB for long term (10 years) recurrence risk predictions in early-stage HR-positive, HER2 negative breast cancer.

Clinical trial identification: Clinical Trials.gov NCT00279448, NCT00032136, and NCT00036270; Netherlands


Introduction

- (CAB) CanAssist Breast is an immunohistochemistry based developed using prognostic test Indian breast cancer patient samples and validated on multiple cohorts from US, Spain, Germany, Austria, Italy.²⁻⁵
- provided CAB accurate and comparable prognostic information in South Asian and European breast cancer patients within 5 years from diagnosis^{4, 5}
- CAB risk stratification was also useful in identifying patients who do not chemotherapy from the require 'clinically high-risk' patients with nodepositive /luminal-B disease³⁻⁵
- Similarly CAB accurately identified patients requiring chemotherapy out of the "clinically low-risk patients".⁴
- CAB stratification risk was independent clinical age parameters, proliferative index (Ki-67) and racial/ethnic differences²⁻⁵
- CAB's low-risk accuracy was on par with that of Oncotype DX/MammaPrint with 83%/85% concordance in patients called low-risk⁵ by both the tests.⁵⁻⁶
- The current study for the first time risk recurrence assesses predictions at 10 vears from diagnosis in a sub-cohort of a randomized clinical prospective trial, TEAM.

Methods IHC: 5 Biomarkers Machine Learning Critical signaling Statistical bathways in tumo Algorithm recurrence **CanAssist-Breast** Risk Score Cut-off 15.5 For Recurrence Low Risk

Fig 1: Generation of CAB risk score: IHC gradings of five biomarkers along with three clinical parameters are used by the support vector machine algorithm to generate a risk score. Based on cut-off of 15.5, each patient is categorised as either low-risk or high-risk for recurrence.

Table 1: Tumor anatomical and therapy characteristics of 434 cohort			
		No. (%)	
	T1	197 (45.4)	Dutch
Tumor Size	T2	229 (52.8)	Dutch
	T3	8 (1.8)	
	NO	137 (31.6)	
Node Status	N1	268 (61.8)	CanAss
	N2	29 (6.6)	on e
Grade	G1	90 (20.7)	
	G2	232 (53.5)	
	G3	112 (25.8)	
Hormonal	Exemestane	221 (50.9)	
therapy	Sequential	213 (49.1)	
Chemotherap	No	344 (79.3)] Dat
У	Yes	90 (20.7)	



Results Risk stratification by CanAssist Breast (CAB) at 10 years Fig 3. CAB risk stratification is significant in total cohort **Overall survival** Distant metastasis-free interval HR=2.91 (1.76-4.82)




Fig 3: Kaplan-Meier curves for event rates in the total cohort: Segregation of patients into low- and high-risk groups for all cause mortality for the total time period and distant recurrences and death due to breast cancer at 10 years

Fig 4. CAB stratifies patients of both arms of hormonal therapy significantly




Fig 4: Kaplan-Meier curves for event rates at 10 years across both the arms of hormonal therapy: Segregation of patients into low- and highrisk groups by CAB in exemestane arm and sequential arm of TEAM trial




Fig 5: Kaplan-Meier event rate curves at 10 years in patients treated with endocrine therapy alone: Segregation of patients into low- and high-risk groups in total cohort, exemestane arm and sequential arm.

Fig 6. CAB risk stratification is useful in node-positive patients






Fig 6: Kaplan-Meier event rate curves at 10 years in patients with node-positive disease: Segregation of node-positive patients into lowand high-risk groups by CAB in total cohort, exemestane arm and sequential arm.





Predictive ability of CAB at 10 years for overall survival

Fig 7. CAB predicts the benefit of exemestane in low-risk and benefit of chemotherapy for high-risk patients

CAB Low-risk: Sequential vs. Exemestane

CAB High-risk: Sequential vs. Exemestane

242 n=

102 n=

Fig 7:Univariate hazard ratios for overall survival at 10 years for CAB low and high-risk patients treated with endocrine therapy only

Table 2. CanAssist Breast risk score has higher and significant hazard ratio compared to clinical parameters

COV

CAB risk risk,

Grade:

T size:

Node sta

Table 2: Multivariate table for hazard ratios for CanAssist Breast risk score and clinical parameters

Conclusions:

- CanAssist Breast recurrence risk predictions are useful till 10 years of disease diagnosis in postmenopausal, hormone receptor-positive, HER-2 negative women
- CanAssist Breast risk stratification is significant in both types of hormonal therapy
- CanAssist Breast recurrence risk predictions are useful to plan therapy in women with the nodepositive disease

References:


- Vel de et al., Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet Vol 377 January 22, 2011 Ramkumar C et al., Development of a Novel Proteomic Risk-Classifier for Prognostication of Patients With Early-Stage Hormone Receptor-Positive Breast Cancer. *Biomarker Insights* 2018; 13: 1-9. Bakre MM et al., Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor positive
- breast cancer patients. Cancer Med 2019; 8: 1755-1764. Doval DC, Mehta A, Somashekhar SP et al. The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin. The
- Breast 2021; 59: 1-7 Gunda A, Basavaraj C, Chandra Prakash SV, Adinarayan M, Kolli R, Eshwaraiah MS, Saura C, et al. A retrospective validation of CanAssist Breast in
- European early-stage breast cancer patient cohort. The Breast 2022; 63: 1-8
- Sengupta AK & Gunda A et al., Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. Cancer Med 2020; 9: 7810-7818.

Acknowledgments

We thank Mr Ramu Kolli, Dr Naveen Krishnamoorthy and Dr Manjula Adinarayan from OncoStem Diagnostics, Bangalore for helping us with IHC experimentation, histopathological work. We thank Geeske Dekker-Ensink from the LUMC for preparing the slides.

Disclosure statement: The first and presenting author, Xi Zhang has no conflict of interest.

OncoStem CanAssist Breast predicts risk of recurrence



variate	Hazard ratio	95% CI	P-value
k score: high Iow risk	2.4872	1.52- 4.08	0.0003
G2+G3 <i>,</i> G1	1.895	0.84-4.26	0.1216
T2+T3, T1	1.3171	0.81- 2.14	0.2647
atus: N+, NO	1.1993	0.69-2.08	0.516

CanAssist Breast predicts the overall survival benefit of exemestane, but not for tamoxifen, for lowrisk and the benefit of chemotherapy for high-risk patients